刘军指出，阿尔茨海默病最明确的危险因素是年龄增长，患者多起病于老年（60岁及以上）或老年前期，且年龄越大患病概率越高。相关数据显示，65岁以 上人群中，年龄每增加5-10岁，发病率增加1倍。若本身携带阿尔茨海默病危险基因，年龄带来的发病风险会进一步放大，成为疾病侵袭的"高危信号"。他 表示，成龙的母亲在退休后发病，首要关联因素是年龄，而非停止工作本身。 相比起工作与否，工作类型与阿尔茨海默病关系更为密切。调查显示，从事体力劳动、服务行业的人员患病的风险要比从事艺术、专业技术及管理的人员更 高。刘军解释："这可能是因为在工作过程中，脑力劳动多的人大脑得到了更充分的锻炼，这也说明多用脑、多与人交流有利于减少阿尔茨海默病的发病风 险。" 早诊早治，抓住"黄金治疗期" 阿尔茨海默病病程漫长，从临床前期到轻度阶段可能长达十余年。患者早期会出现记忆力减退、对时间地点和物品的判断力下降、日常生活能力下降、精神 行为异常等症状，很多患者及其家属往往将这些症状归结于"年龄大了"，导致很多患者就诊时已进入中晚期，错过了疾病早期的"黄金治疗期"。 近日，知名电影人成龙撰文回忆母亲在退休后罹患阿尔茨海默病、记忆逐渐流逝的经历，并呼吁 ...

12月22日晚间，复星医药（SH600196，股价27.09元，市值723.4亿元）发布关于回复上海证券交易所就 绿谷（上海）医药科技有限公司（以下简称绿谷医药）投资事项监管工作函（以下简称回复函）的公 告，披露了关于其具体交易方式、后续整合以及治疗阿尔茨海默病的药物——甘露特钠胶囊（商品 名"九期一"）后续临床试验的进展等内容。 《每日经济新闻》记者了解到，对于这笔交易，市场最为关注的问题，还是复星医药收购绿谷医药若完 成，"何时才能将'九期一'重新推向市场"。 根据复星医药公告，甘露特钠胶囊修订后的上市后确证性临床试验，目前已获国家药监局药审中心认 可。基于该项目临床方案预估，2027年底全部受试者可完成入组，2029年初可完成相关研究并读出数 据，2029年上半年向国家药监局递交临床试验总结报告等资料。 此外，复星医药公告还披露，此前，绿谷医药曾以不合理会议名义支付讲课费等违规宣传销售甘露特钠 胶囊，并因此被浦东新区市场监督管理局作出行政处罚并处40万元罚款。 对此，复星医药方面称，前述处罚未对绿谷医药经营造成重大不利影响。同时，基于审计报告及尽调， 未发现绿谷医药存在隐性大额债务和资金被占用的情况。 ...

Core Viewpoint - The acquisition of Green Valley Pharmaceutical by Fosun Pharma for 1.412 billion yuan has led to a significant drop in the company's stock price and triggered regulatory scrutiny from the Shanghai Stock Exchange [3][4]. Group 1: Acquisition Details - Fosun Pharma aims to acquire Green Valley Pharmaceutical primarily to obtain the Alzheimer's drug, Ganluo Sodium Capsule, which has faced efficacy controversies since its conditional approval in November 2019 [3][4]. - The acquisition involves a combination of "acquiring existing equity + subscribing to new registered capital," with a phased payment structure: an initial payment of 635 million yuan at closing, followed by another 635 million yuan based on the target company's R&D progress over three years [5]. - The founder-controlled entity of Green Valley will pledge 10% of the company's shares to secure potential losses from the acquisition, enhancing transaction safety [5]. Group 2: Clinical Trial Progress - Fosun Pharma has communicated that the clinical trial for Ganluo Sodium Capsule is being revised to meet the latest regulatory standards, extending the double-blind treatment period from 36 weeks to 48 weeks and increasing the sample size from 1,312 to 1,950 participants [6]. - As of December 15, 2025, 580 participants have been enrolled in the clinical study, with projections indicating that all participants could be enrolled by the end of 2027, and data could be available by early 2029 [7].

【#复星医药14.12亿元投资带崩股价##复星医药回应收购AD药物争议# 】或许令复星医药 （600196.SH；02196.HK）没有想到的是，公司上周抛出的拟14.12亿元收购绿谷医药行动，居然会"带 崩"公司股价，且收到了上海证券交易所的《监管工作函》。 12月22日晚间，针对投资绿谷医药具体交易方式、阿尔茨海默病（AD）药物甘露特钠胶囊临床进展及 后续整合等问题，复星医药方面进行了回应。 甘露特钠胶囊是绿谷医药的主要品种，该药曾于2019年11月获国家药监局有条件批准上市，用于轻度至 中度阿尔茨海默病治疗，彼时成为继2002年美金刚（治疗中重度至重度阿尔茨海默型痴呆）获批上市17 年后，全球首个获批上市的AD治疗药物。 ...

Core Viewpoint - Fosun Pharma is acquiring a controlling stake in Green Valley Pharmaceutical for approximately 14.12 billion RMB, despite the core product, Manzamine Sodium Capsule, being off the market due to regulatory issues. The acquisition has raised concerns in the capital market regarding the timeline for the product's return to commercialization [2][3][4]. Group 1: Acquisition Details - The acquisition will be executed through a combination of stock transfer and subscription to new registered capital, resulting in Fosun Pharma holding 51% of Green Valley Pharmaceutical [4]. - The payment for the acquisition will be made in installments, with an initial payment of 635 million RMB at the time of closing, and the remaining amount contingent on the progress of Green Valley's research and development [4]. - Green Valley's founder will pledge 10% of the company's shares post-acquisition to mitigate potential risks [4]. Group 2: Clinical Trial and Product Timeline - The revised post-marketing confirmatory clinical trial for Manzamine Sodium Capsule has been approved, with full enrollment expected by the end of 2027 and data readout in early 2029 [2][7]. - The product has been off the market since November 2024 due to the expiration of its registration certificate and will require successful completion of the clinical trial and regulatory approval before resuming sales [7][8]. Group 3: Financial and Compliance Status - Green Valley Pharmaceutical has faced regulatory scrutiny, including a 400,000 RMB fine for improper promotional practices, but this has not significantly impacted its operations [9][10]. - An audit revealed no hidden large debts or misuse of funds within Green Valley, indicating a stable financial position prior to the acquisition [10][12]. - As of September 30, 2025, Green Valley's assets and liabilities were 806 million RMB and 795 million RMB, respectively, which have a limited impact on Fosun Pharma's overall financial structure [12]. Group 4: Market Competition and Future Risks - The market for Alzheimer's treatments is competitive, with six other drugs already approved, which may affect the sales performance of Manzamine Sodium Capsule upon its return to the market [8]. - The timeline for the product's re-commercialization has been extended to around 2029, raising concerns about market dynamics and reimbursement conditions at that time [8].

Core Insights - The article narrates the emotional journey of a caregiver, Zhu Maomao, who reflects on her experiences caring for her mother suffering from bipolar disorder and Alzheimer's disease, highlighting the complexities of their relationship and the impact of illness on family dynamics [1][2][4][5][7][19]. Group 1: Caregiver Experience - Zhu Maomao describes her role as a full-time mother and caregiver, emphasizing the challenges faced while raising her daughter, who has autism, alongside her mother's mental health struggles [4][5]. - The narrative reveals the emotional toll of caregiving, including feelings of helplessness and the transformation of the mother-daughter relationship as they navigate illness together [7][19]. - Zhu Maomao's reflections on her mother's decline illustrate the gradual loss of independence and the caregiver's evolving role, leading to a reversal of traditional family roles [19][20]. Group 2: Mother's Illness Journey - The article details the progression of the mother's bipolar disorder and subsequent diagnosis of early-onset Alzheimer's disease, including specific symptoms and changes in behavior over time [10][11][15]. - It highlights the mother's emotional resilience and moments of clarity amidst her illness, showcasing her attempts to maintain a connection with her family, particularly her granddaughter [5][15][25]. - The narrative also discusses the impact of medication on the mother's health and quality of life, including side effects and the challenges of managing her care [14][20]. Group 3: Family Dynamics - The relationship between Zhu Maomao and her mother is characterized by a blend of love, frustration, and a search for understanding, as they both cope with their respective mental health issues [31][32]. - The article touches on the societal perceptions of success and failure, contrasting the mother's life experiences with conventional standards, ultimately recognizing her wisdom and resilience as invaluable [31][32]. - The story concludes with reflections on loss and the complexities of familial love, emphasizing the importance of understanding and appreciating the sacrifices made by caregivers [34][35].

Core Viewpoint - The drug Gantoret Sodium Capsule (brand name: Jiuyi) for Alzheimer's disease has become scarce, leading to widespread concern about the difficulties patients face in obtaining medication [2][4][5] Group 1: Supply Issues - Since 2025, Gantoret Sodium Capsule has faced prescription difficulties in hospitals and supply shortages on online platforms [4][5] - The manufacturer, Green Valley Pharmaceutical Technology, acknowledged the supply issues and is in communication with relevant authorities to address the situation [2][4] - Reports indicate that the drug's market price has increased by approximately 40% in recent months, with some pharmacies listing prices as high as 5000 yuan per box [5][6] Group 2: Market Dynamics - The drug was first approved for conditional listing in November 2019 and officially launched in December 2019, allowing patients to purchase it with a doctor's prescription [4][6] - The initial price of the drug was set at 895 yuan per box, but it was later included in the national medical insurance directory, reducing the price to 296 yuan per box [6][7] - The current monthly cost for patients using Gantoret Sodium is approximately 1184 yuan, significantly lower than the combined cost of traditional treatments [6][7] Group 3: Disease Context - Alzheimer's disease is a major neurodegenerative condition affecting over 55 million people globally, with China having the highest number of patients [8] - The treatment options for Alzheimer's disease are limited, with Gantoret Sodium being one of the few drugs that can improve cognitive function without worsening the condition [8][9] - The drug was conditionally approved due to the urgent need for treatment options, despite some initial concerns regarding long-term safety data [9]